Search

everythinglearnresearchcommunity

for

Search:↓

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Upadacitinib improved multiple immune-related conditions in one patient.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.